Investigation of the Cylex® ImmuKnow® Assay

Indiana University45 enrolled

Overview

Currently, there is no accurate way of predicting the occurrence of Graft vs Host Disease (GvHD) or infection. The purpose of this study is to analyze blood with the ImmuKnow® Assay to see if doctors can detect which patients are at risk for GvHD and for getting an infection before they occur.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Leukemia Non-Hodgkin's Lymphoma Chronic Lymphocytic Leukemia Hodgkin's Disease Multiple Myeloma Myelodysplastic Syndromes Myeloproliferative Disorders Aplastic Anemia

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients who are undergoing allogeneic HSCT using a myeloablative preparative regimen for any of the following disorders are eligible: 1. Acute leukemia 2. Non-Hodgkin's Lymphoma 3. Chronic lymphocytic leukemia 4. Hodgkin's disease 5. Multiple myeloma 6. Myelodysplastic Syndromes 7. Myeloproliferative Disorders 8. Aplastic Anemia 9. Chronic myelogenous leukemia

Locations (1)

Indiana Universtiy Simon Cancer Center

Indianapolis, Indiana, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.